During a Congressional hearing, Novo Nordisk CEO Lars Jorgensen faced pressure from lawmakers regarding the high prices of weight-loss drugs Ozempic and Wegovy. While Jorgensen attributed some costs to pharmacy benefit managers, he agreed to meet with them to discuss potential price reductions.
held a hearing on Tuesday to discuss popular drug maker Novo Nordisk lowering prices for blockbuster weight-loss drugs Ozempic and Wegovy .
C. Michael White is a professor in the School of Pharmacy at the University of Connecticut. He said some"They're going to cost you a little over $1,000 a month," said White. "It is clear patients too often struggle to navigate the complex U.S. healthcare system," said Jorgensen.
Ozempic Wegovy Novo Nordisk Drug Prices Pharmacy Benefit Managers
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk CEO Defends Ozempic Price In Senate TestimonyTy Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
Read more »
Bernie Sanders grills Novo Nordisk CEO on price of Ozempic, other weight-loss drugsSen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes medications, Ozempic and Wegovy.
Read more »
Novo Nordisk CEO Grilled Over High Ozempic and Wegovy PricesLawmakers grilled Novo Nordisk CEO Lars Jorgensen over the high cost of weight-loss drugs Ozempic and Wegovy during a Tuesday hearing. Jorgensen placed some blame on pharmacy benefits managers, claiming they take 74 cents of every dollar the company makes.
Read more »
Novo Nordisk CEO Defends High Ozempic, Wegovy Prices at Congressional HearingNovo Nordisk CEO Lars Jorgensen faced intense scrutiny from lawmakers on Tuesday over the high prices of the company's weight-loss drugs Ozempic and Wegovy. Jorgensen argued that pharmacy benefit managers (PBMs) are responsible for a significant portion of drug costs, but lawmakers pressed him to take action to lower prices for American patients.
Read more »
Ozempic, Wegovy maker Novo Nordisk faces hearing over high cost of weight loss drugsBlockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
Read more »
Ahead of Novo Nordisk Hearing, 250 Clinicians Demand Affordable Access to Ozempic and WegovyNewswire Editor is a Common Dreams staff position.
Read more »